Can an aspirin a day treat Parkinson’s disease (PD)? Not exactly, but the idea made headlines a few weeks ago, after scientists discovered that a key ingredient of aspirin might have potential to block the loss of brain cells in neurological diseases like PD and Alzheimer’s. As with every science headline, PDF asks, “what does it mean for people with PD?” In this case, we asked Michael Schwarzschild, M.D., Ph.D., of MassGeneral Institute of Neurodegenerative Disease, a well-known PD scientist who has also studied aspirin and ibuprofen in relation to PD. Here are his insights.
I’m a scientist and a doctor. Because of funding from the Parkinson’s Disease Foundation, I’m spending my career as a member of the team ending PD. But we need your help. As a young neurologist, PDF’s investment in my two-year fellowship — and its annual investment in my fellow research leaders in the amount of $4.6 million — enabled me and others to join the team fighting PD. But we need your donation to help us meet our goal of ending the disease. When you donate by Thursday, December 31st, your donation will be doubled by the PDF Board of Directors… Read More
The Society for Neuroscience annual meeting, which took place last week in Chicago, IL, is a place where the latest preliminary data in neuroscience is presented. True to form, there was an interesting abstract presented by Fernando Pagan, M.D. and colleagues from Georgetown University Hospital which suggested a potential treatment for those with Parkinson’s disease (PD). At the heart of the presentation, Dr. Pagan and colleagues reported that in a small trial, an anti-cancer drug called nilotinib was able to reverse both the movement symptoms and cognitive decline of people with PD involved in the study.
How do we capture rising stars in science and encourage them to focus their attention on Parkinson’s? This is a question that PDF — in its quest to help solve, treat and end PD — has been evaluating since its creation 60 years ago. In fact, PDF’s focus on catching rising stars in PD is the reason why we have prioritized funding for the training of early-career neurologists — more than 100 of them over the years — in PD research and care. It is also the reason we have supported the research of more than 250 early-career basic scientists over the same… Read More
A few weeks ago, I attended my first American Academy of Neurology (AAN) meeting, which was held in Washington, DC. This was the 67th annual meeting of the AAN, which brings together 10,000 neurologists and neuroscientists working to bring the best patient care and innovative research to the field of neurology. What should the PD community know about this gathering of professionals fighting their disease? Among the many highlights, here are a few of the more notable ones:
Which part of living with Parkinson’s disease should be the priority for scientists to study? For Diane Cook the answer is: cognitive issues. She submitted her answer through the Second Annual PDF Community Choice Research Awards survey. Now she is urging you to share yours by Thursday, April 30. Diane worked closely with PDF to develop the first Community Choice Research Awards survey last year, which are a “people’s choice” for PD research grants. The ProjectSpark Foundation run by Diane’s children donated funds for the awards. Hear from Diane about why the “people’s choice” awards are critical for PD research, why she… Read More